Presence

North America Abbott’s Xience V is a market-leading drug-eluting stent in the United States and Europe for treating coronary artery disease. An estimated 7 million people worldwide die each year from coronary artery disease — the number one killer in the United States.

South America Chagas disease is a tropical parasitic disease endemic in Latin America. It afflicts an estimated 15 million people in Mexico, Central America and South America. If left untreated, Chagas is often fatal. In 2008, we launched a test for Chagas on our Abbott Prism blood-screening instrument.

Europe In 2008, in Germany, Humira became the number one prescribed biologic, helping thousands of patients with certain autoimmune diseases. Abbott continues its immunology research in Ludwigshafen, Germany, where early development work on Humira was first conducted.

Africa The hepatitis C virus (HCV) affects approximately 3 percent of the world’s population, with alarming rates in Africa. Abbott is conducting early-stage HCV research for medicines that could improve efficacy and tolerability over current therapies. We also market HCV diagnostic tests around the world.

India India is expected to have the largest incidence of diabetes in the world: an estimated 40 million people by 2015. Abbott markets its diabetes nutritional products, diagnostic tests and blood glucose monitors in India and around the world.

South Asia As personal incomes increase in markets such as China and Southeast Asia, parents seek better nutrition for their children. This has led to increased demand for Abbott nutritional products. To keep pace with growing global demand, we opened a new manufacturing facility in Singapore in early 2009.